DeepQure Showcases Extravascular RDN Technology at WCET 2025

DeepQure, a medical device company developing extravascular renal denervation (RDN) systems, announced on September 16 that it presented the advantages of its extravascular approach at the 42nd World Congress of Endourology and Technology (WCET 2025).

WCET 2025, organized by the global endourology society, was held in Phoenix, Arizona, USA, from September 8–12. The congress is a leading platform where urologists from around the world share updates on the latest therapies and medical technologies.

DeepQure took part in a semi-live surgery session during a joint meeting of the Urologic Robotic Surgery Society and the Focal Therapy Society. On the morning of September 12, the company delivered a presentation—drawing on its clinical cases—titled “Extravascular Renal Denervation for the Treatment of Resistant Hypertension.”

DeepQure’s flagship product, HyperQure™, is a laparoscopic surgical device developed over roughly 10 years of research and preclinical work by Professor Chang-Wook Jeong’s team at Seoul National University Hospital. Designed to overcome limitations of intravascular RDN, HyperQure™ employs an extravascular route as an innovative, laparoscopic RDN system.

The company is currently conducting clinical trials of the extravascular RDN approach in patients with resistant hypertension in Korea and overseas. The domestic study is in its final stages, and in the United States trials are underway at five major university hospitals.

A DeepQure spokesperson said, “By completing the ongoing domestic and international trials, we plan to demonstrate the safety and efficacy of HyperQure™ and move forward with full-scale entry into global markets.”

Source